Statistical analysis
ADVERSE EVENTS, RVF
This phase I first-in-human trial aimed to describe the safety, tolerability, and immunogenicity of ChAdOx1 RVF. The number of participants in each vaccine dose group allowed a descriptive analysis of the frequency and magnitude of adverse events following vaccination, rather than statistical significance testing for safety differences between individuals. Immunological data were visualised and analysed using non-parametric tests on GraphPad Prism version 9 (GraphPad Software Inc., California, USA), with a two-sided alpha of 0·05 for statistical significance.